Michael Listgarten
Consigliere Generale presso RAPT THERAPEUTICS, INC.
Posizioni attive di Michael Listgarten
Società | Posizione | Inizio | Fine |
---|---|---|---|
RAPT THERAPEUTICS, INC. | Consigliere Generale | 03/05/2023 | - |
Storia della carriera di Michael Listgarten
Precedenti posizioni note di Michael Listgarten
Società | Posizione | Inizio | Fine |
---|---|---|---|
ADAMAS PHARMACEUTICALS, INC. | Responsabile della Conformità | 01/02/2021 | 01/11/2021 |
PRINCIPIA BIOPHARMA INC. | Corporate Officer/Principal | 01/06/2020 | 01/12/2020 |
Formazione di Michael Listgarten
University of Pennsylvania | Undergraduate Degree |
The Trustees of Columbia University in The City of New York | Graduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 6 |
Posizioni
General Counsel | 1 |
Undergraduate Degree | 1 |
Graduate Degree | 1 |
Settori
Health Technology | 4 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
RAPT THERAPEUTICS, INC. | Health Technology |
Aziende private | 2 |
---|---|
Adamas Pharmaceuticals LLC
Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
Principia Biopharma, Inc.
Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- Michael Listgarten
- Esperienza